Docoh
Loading...

ARWR Arrowhead Pharmaceuticals

News

Pro users get this 30m faster
Arrowhead Pharmaceuticals Initiates Phase 2b Study Of ARO-APOC3 For Treatment of Mixed Dyslipidemia
30 Sep 21
Biotech, News, General
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has dosed the first patient in AROAPOC3-2002, a Phase 2b clinical study of ARO-APOC3 in adults with mixed dyslipidemia. ARO-APOC3 is the
ARWR: New Program Targeting Complement C3 Highlights Expanding Pipeline…
10 Aug 21
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT
HC Wainwright & Co. Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $100
10 Aug 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and raises the price target from $95 to $100.
Chardan Capital Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $94
6 Aug 21
News, Price Target, Analyst Ratings
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $97 to $94.
Recap: Arrowhead Pharmaceuticals Q3 Earnings
5 Aug 21
Earnings
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08% year over year to ($0.29), which missed the estimate of ($0.20).
Arrowhead Pharmaceuticals Q3 EPS $(0.29) Misses $(0.20) Estimate, Sales $45.89M Beat $37.52M Estimate
5 Aug 21
Earnings, News
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.20) by 45 percent. This is a 123.08 percent decrease over losses of $(0.13) per
Earnings Scheduled For August 5, 2021
5 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

Press releases

Pro users get this 30m faster
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
12 Oct 21
Press Releases
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that on October 26, 2021, at 3:00 p.m. ET it will host a key opinion leader (KOL) webinar on ARO-C3, the company's investigational RNA interference (RNAi)
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
30 Sep 21
Press Releases
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has dosed the first patient in AROAPOC3-2002, a Phase 2b clinical study of ARO-APOC3 in adults with mixed dyslipidemia. ARO-APOC3 is the company's
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
29 Sep 21
Press Releases
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Chardan's 5th Annual Genetic Medicines Conference – October 4-5, 2021 October 4,
Arrowhead Earns $10 Million Phase 1 Milestone Payment
28 Sep 21
Press Releases
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it earned a $10 million milestone payment from Janssen Pharmaceuticals, Inc., (Janssen) part of the Janssen Pharmaceutical Companies of Johnson &
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
1 Sep 21
Press Releases
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi's 16th Annual BioPharma Virtual Conference – September 8-10, 2021 September 9,
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
29 Jul 21
Press Releases
- Full enrollment reached in Phase 2 SEQUOIA study of ARO-AAT Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug